Medication info
Linadipodu Duo Tablet 2.5/1000mg (Linagliptin, Metformin)

Linadipodu Duo Tablet 2.5/1000mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Bright pink, biconvex, oval film-coated tablets
Packaging
30 tablets/bottle, 30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201901617 · Approved 2019.03.18 · Insurance code 670609260

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should comprise linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to comprise linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for use, 3. Administration with caution to the following patients). 5. Patients whose blood glucose is not adequately controlled with concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to comprise linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for use, 3. Administration with caution to the following patients). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication assists patients with type 2 diabetes in controlling blood sugar more effectively when used alongside dietary changes and exercise. Linagliptin and metformin work together to help improve blood sugar control, making it suitable for those struggling with blood sugar management. This drug facilitates smoother management of diabetes and contributes to maintaining the patients' health. It is used to improve blood sugar control with consistent administration.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should comprise linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to comprise linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for use, 3. Administration with caution to the following patients). 5. Patients whose blood glucose is not adequately controlled with concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to comprise linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for use, 3. Administration with caution to the following patients). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This drug contains two main ingredients, linagliptin and metformin, and is used for the treatment of type 2 diabetes. One of the most important precautions when taking this medication is the risk of lactic acidosis, a serious metabolic complication. Lactic acidosis is rare but can occur when kidney function deteriorates rapidly or there are issues with heart or liver function; therefore, patients with impaired kidney function or those who are seriously ill or dehydrated should not take this medication. Additionally, individuals allergic to the ingredients in this drug or those with type 1 diabetes, diabetic ketoacidosis, pregnant women, or nursing mothers should not use this medication. When taken with other diabetes treatments that carry a risk of hypoglycemia, caution is necessary as symptoms of hypoglycemia may occur, and dosage adjustments of other medications may be required as necessary. Elderly patients with reduced kidney function should be particularly cautious and should have regular kidney function tests. The medication may need to be temporarily discontinued before and after acute illness or surgery. Rare side effects such as acute pancreatitis or skin blistering have been reported, so if severe abdominal pain or skin rashes occur, patients should consult a physician immediately. The metformin ingredient may lower vitamin B12 levels; therefore, regular monitoring of vitamin B12 levels is advisable during prolonged use. This medication can interact with other drugs, so patients must inform their doctor or pharmacist about any other medications they are taking, especially when combined with drugs that may affect kidney function. Women who are pregnant or planning to become pregnant should avoid this medication; insulin therapy is recommended for blood sugar control. This drug is not recommended for children under 10 years old and adolescents aged 10 to 17, as safety and efficacy have not been established. The medication should be stored away from moisture and in a place out of the reach of children, and its effect on driving or operating machinery is unknown. In case of overdose, serious side effects like lactic acidosis may occur, requiring immediate medical attention.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorders
  • cough
  • loss of appetite
Show 119 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering dermatitis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • loss of appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer’s dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • metastasis to the liver
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • stomach cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • renal transplantation failure
  • pneumonia
  • hypertension
  • anxiety
  • depression
  • insomnia
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • pruritus
  • confusion state
  • nocturia
  • dermatitis
  • hypertension
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • upper abdominal pain
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • dizziness
  • sensory loss
  • discomfort in the chest
  • weakness
  • pain
  • epistaxis
  • oropharyngeal pain
  • voice disorders
  • nosebleeds
  • hearing loss
  • erectile dysfunction
  • goiter
  • benign prostatic hyperplasia
  • androgenetic alopecia
  • hyperhidrosis
  • hair loss
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air and moisture, and it is best kept at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the drug's effectiveness and prevent degradation.

Appearance and packaging

Appearance

Bright pink, biconvex, oval film-coated tablets

Package unit

30 tablets/bottle, 30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.